Autoimmune hepatitis (AIH) is a chronic inflammatory liver disorder that is usually characterized by circulating autoantibodies and elevated serum globulin levels. The pathology of the disease is that of a gradual hepatocellular inflammation that cannot be explained by more common etiologies of chronic liver disease, such as alcohol-related liver disease, viral hepatitis, hereditary liver disorders or exposure to hepatotoxic substances. The natural history of AIH may progress from acute hepatitis to chronic liver disease and ultimately to cirrhosis. In the general population, it has a low incidence (1 per 100000). The pathology more commonly affects women and manifests at childbearing age, but it can occur at any age.
Autoimmune disorders and having positive autoantibodies are risk factors for obstetric complications as well as perinatal morbidity and mortality. The data regarding pregnancy in women with AIH is limited, and few studies exist on pregnancy outcomes in these women. However, the number of pregnancies reported in these patients is becoming more frequent due to better clinical management as well as high-quality prenatal and antenatal care. Currently, pregnancy and childbirth in AIH appear to be safe for both mother and child. In this review article, we aim to report on the diagnosis and management of AIH during pregnancy.
The probable theory for the pathogenesis of autoimmune hepatitis – in both pregnant women and the general population – is that the disease results from an environmental trigger in an individual who is genetically predisposed. The precise mechanism between the genes and the autoimmune process are still unknown. However, at the molecular level, they are believed to involve an antigen, a major histocompatibility complex (MHC), and a T cell receptor, which together form a complex in which complementary-determining regions identify and contact the antigen-MHC complex. The suggested environmental triggers that lead to this T cell-mediated immune response targeting the liver include viruses, medications, herbal supplements, and even immunizations. However, in most cases, the particular inducer of autoimmunity is never identified.
In the general population, autoimmune hepatitis has a low incidence (1 per 100000). The disease more commonly affects women and manifests at childbearing age, but the first episode of AIH can occur at any age. For type 1 AIH, the female to male ratio is 4 to 1, but, for type 2 AIH, the ratio is 10 to 1.
The pathology of autoimmune hepatitis is that of a gradual hepatocellular inflammation that cannot be explained by the common etiologies of chronic liver disease, such as alcohol-related liver disease, viral hepatitis, exposure to hepatotoxic substances, and hereditary liver disorders. The natural history of the disease may progress from acute hepatitis to chronic liver disease and ultimately to cirrhosis. The probable mechanism of obstetric complications in women with AIH is target involvement of the maternal-fetal interface structures by autoantibodies and natural immune cells activated by the disease. These interface structures that get targeted include cellular components of intervillous space, endothelial tissue of spiral veins, and superficial epithelial cells of the decidua. This process leads to increased risk of first-trimester miscarriage and preterm delivery. Thrombosis is another complication that occurs due to endothelial damage and complement system activation; these can lead to worse perinatal outcomes.
Histopathology showing the following typical features can confirm the diagnosis of autoimmune hepatitis:
The clinical presentation of autoimmune hepatitis can be highly variable: it can present as either an acute or chronic illness with a fluctuating pattern. It can also be discovered incidentally in completely asymptomatic individuals on routine laboratory testing such as those required for insurance, for employment, or before blood donation. Patients can present with debilitating symptoms such as malaise, anorexia, fatigue, and weight loss. The patients can also present with acute liver failure as an initial presentation with jaundice, ascites, and coagulopathy.
Physical findings expected of AIH, in both pregnant women and the general population, range from a normal physical examination to findings suggestive of cirrhosis or liver failure (e.g., jaundice, ascites, splenomegaly).
Also, individuals with AIH may present with a coexisting extrahepatic disorder, which may also be autoimmune mediated. The common autoimmune disorders associated with AIH include autoimmune thyroiditis, rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes mellitus, celiac disease, and ulcerative colitis.
The diagnosis of autoimmune hepatitis is similar in both pregnant women and the general population and has its basis representative serologic and histologic findings as well as the exclusion of other types of chronic liver disease. Often, the disease can be strongly suspected based upon clinical and laboratory features, and thus, a liver biopsy is not always necessary in patients with characteristic findings on non-invasive testing.
For individuals with consistent clinical or laboratory features, it is recommended to obtain serum anti-nuclear (ANA), anti-smooth muscle (ASMA), anti-mitochondrial (AMA), and anti-liver/kidney microsomal-1 (ALKM-1) antibodies, as well as either an immunoglobulin G (IgG) or gamma globulin level. For those who are negative for these autoantibodies, it is recommended to obtain anti-soluble liver antigen/liver pancreas antibody, anti-actin antibodies, and atypical perinuclear antineutrophil cytoplasmic (p-ANCA) antibodies.
Patients with AIH historically categorize into two disease subtypes according to the nature of autoantibodies :
Roughly 20 percent of individuals who present with features of AIH lack circulating ANA, ASMA, or ALKM-1 antibodies. These individuals usually present as having autoantibody-negative autoimmune hepatitis. Often, the only indication that AIH is the underlying disease is a therapeutic response to anti-inflammatory therapy.
In specific instances, it may be preferable to obtain a liver biopsy in individuals in whom autoimmune hepatitis is suspected because histologic assessment can confirm the diagnosis and help to guide treatment. Histologic evaluation is especially useful as part of the diagnostic evaluation for those who have few or atypical findings, negative autoantibodies, and/or normal IgG levels.
After obtaining a liver biopsy, the diagnostic confirmation is by histology showing typical features (see Histopathology section).
The course of autoimmune hepatitis during pregnancy is unpredictable. Though the literature is limited, up to 20% of patients with AIH will flare during pregnancy, and this is associated with a high rate of fetal and maternal complications. Thus, women with AIH should be counseled to delay pregnancy at least one year until their disease is under optimal control.
The preferred treatment for AIH during pregnancy include glucocorticoids at the lowest possible doses, alone or in combination with azathioprine. Azathioprine is a US FDA pregnancy category D medication, and providers should prescribe it only if the benefit justifies the potential risks to the fetus. Meanwhile, prednisone is a US FDA pregnancy category C medication and does not extensively cross the placenta, is not associated with teratogenicity in humans, and is the preferred treatment for control of disease activity during pregnancy in women with AIH. Though the studies are limited, azathioprine, and prednisone use in pregnant women with AIH did not increase the risk of adverse fetal and maternal outcomes, so optimal AIH control outweighs the risks associated with these medications. Thus, treatment should continue, and the patient monitored closely for flares. Other medications used for the treatment of AIH, including mycophenolate mofetil (MMF) and tacrolimus, are contraindicated in pregnancy because they cause congenital malformations/congenital disabilities, premature birth, low birth weight, and severe infections in the expectant mother.
AIH Treatment and Breastfeeding:
Breastfeeding is also safe with prednisone. Azathioprine gets excreted at low levels in breast milk, and the majority of experts recommend continuing azathioprine use during breastfeeding despite manufacturers’ recommendations against using them during lactation. There are no data on budesonide and mycophenolate and breastfeeding.
Management of AIH Flare:
During flares, management of pregnant patients with AIH should be similar to non-pregnant patients, with higher doses of prednisone and/or the addition of azathioprine.
Patients with Cirrhosis and AIH:
Cirrhosis can occur as an initial presentation at the time of diagnosis of AIH in up to 40% of patients. Therefore, providers will not infrequently encounter pregnant females with cirrhosis secondary to AIH. Pregnancy in compensated cirrhotic women is no longer feared, nor is it contraindicated, but it correlates with increased rates of preeclampsia, low birth weight, preterm delivery, and neonatal death with increased risk of maternal mortality and complications. In contrast, patients with a MELD (Model for End-Stage Liver Disease) score of greater than 10 are at higher risk for poor maternal and fetal outcomes, with increased risk of decompensation and maternal mortality of up to 7.8%. This group of patients should have thorough discussions with their obstetrician and hepatologist regarding elective termination of pregnancy, surrogate pregnancy, and delaying pregnancy until after liver transplantation. During pregnancy, compensatory dilation of collateral veins that join the portal circulation and the azygos vein occurs, causing expansion of the circulating blood volume and extrinsic compression of the inferior vena cava by the pregnant uterus, leading to increased portal hypertension and variceal bleeding, especially during the third trimester and labor and delivery. This situation is the most common complication and cause of maternal morbidity and mortality. Thus, all patients should have an upper endoscopy for identification of, and potential prophylactic endoscopic variceal ligation of high-risk varices – especially around 28 weeks of gestation when maximum volume expansion occurs. Management of other complications of portal hypertension such as hepatic encephalopathy and ascites should be per the guidelines established for the general population.
AIH may flare with the return of normal immunity after delivery, and, in fact, flares are twice as frequent in the postpartum period during pregnancy. The reported incidence of flares is around 20 to 50% of patients postpartum. Therefore, recommendations are that the patient should be followed by a hepatologist closely. The patient's liver function tests and immunoglobulin G (IgG) level should be monitored at delivery and then at 4-to-6 week intervals during the first three months postpartum.
Autoimmune hepatitis has an array of clinical phenotypes. For this reason, it appears in the differential diagnosis for patients presenting with abnormal liver biochemical tests, cirrhosis, acute hepatitis, or acute liver failure. Furthermore, even with the establishment of diagnostic criteria, there are still issues to be clarified attributable to its variability, such as autoantibody-negative AIH, drug-induced AIH, AIH sharing features with PBC or PSC (i.e., overlap syndrome), and also rarely, post-transplant de novo AIH.
Pregnancy in patients with autoimmune hepatitis is associated with an increased risk of fetal complications and maternal complications. However, data shows that the number of pregnancies reported in women with AIH is becoming more frequent due to better clinical management as well as high-quality prenatal and antenatal care. Currently, pregnancy and childbirth in AIH appear to be safe for both mother and child.
Pregnant women with AIH should be counseled against pregnancy in the context of cirrhosis (MELD score greater than 10), primarily due to the risk of gastroesophageal variceal bleed, although ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, and hepatorenal syndrome can present as well.
Given the elevated rate of fetal complications, including prematurity and death, women with autoimmune hepatitis should be counseled to delay pregnancy until the AIH is under reasonable control for at least one year. Furthermore, these women should receive high-quality prenatal and antenatal care and follow closely with a specialist physician trained in the management of AIH during and after pregnancy. They should be advised to continue to take their medications under medical supervision and to see their healthcare provider regularly.
Patients should be counseled to eat a balanced, healthy diet and to avoid becoming obese, as obesity potentially increases the risk of fatty liver disease, which can worsen AIH. Patients should receive counsel to avoid all types of alcoholic beverages, including beer, wine, and liquor because they can all cause fatty liver and additional liver damage. Furthermore, certain herbs can cause severe liver injury, and some have links with triggering AIH. This reaction is why patients should be advised to avoid seeking any herbal treatment for their liver disease.
Women with autoimmune hepatitis have an increased risk of adverse outcomes in pregnancy and neonatal complications. It is important that these women undergo close surveillance, both prenatally and antenatally, by obstetricians, primary caregivers, nurse practitioners, and hepatologists working closely together. Therefore, autoimmune hepatitis requires an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. [Level V]
The outlook for women with AIH who get pregnant is guarded. Those with the more severe disease tend to have poor fetal outcomes despite therapy.
|||Braga AC,Vasconcelos C,Braga J, Pregnancy with autoimmune hepatitis. Gastroenterology and hepatology from bed to bench. 2016 Summer; [PubMed PMID: 27458515]|
|||Manns MP,Czaja AJ,Gorham JD,Krawitt EL,Mieli-Vergani G,Vergani D,Vierling JM, Diagnosis and management of autoimmune hepatitis. Hepatology (Baltimore, Md.). 2010 Jun; [PubMed PMID: 20513004]|
|||Peters MG, Management of Autoimmune Hepatitis in Pregnant Women. Gastroenterology [PubMed PMID: 28867984]|
|||Orgul G,Ozkan EU,Celik HT,Beksac MS, Autoimmune hepatitis and pregnancy: report of two cases with different maternal outcomes. Clinical and experimental hepatology. 2017 Dec; [PubMed PMID: 29255809]|
|||Colle I,Hautekeete M, Remission of autoimmune hepatitis during pregnancy: a report of two cases. Liver. 1999 Feb; [PubMed PMID: 9928767]|
|||Heneghan MA,Norris SM,O'Grady JG,Harrison PM,McFarlane IG, Management and outcome of pregnancy in autoimmune hepatitis. Gut. 2001 Jan; [PubMed PMID: 11115829]|
|||Westbrook RH,Yeoman AD,Kriese S,Heneghan MA, Outcomes of pregnancy in women with autoimmune hepatitis. Journal of autoimmunity. 2012 May; [PubMed PMID: 22261501]|
|||Danielsson Borssén Å,Wallerstedt S,Nyhlin N,Bergquist A,Lindgren S,Almer S,Werner M, Pregnancy and childbirth in women with autoimmune hepatitis is safe, even in compensated cirrhosis. Scandinavian journal of gastroenterology. 2016; [PubMed PMID: 26631429]|
|||Sebode M,Hartl J,Vergani D,Lohse AW, Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda. Liver international : official journal of the International Association for the Study of the Liver. 2018 Jan; [PubMed PMID: 28432836]|
|||Lohse AW,Herkel J,Weiler-Normann C, Can Understanding the Pathogenesis of Autoimmune Hepatitis Lead to Rational Therapy? Digestive diseases (Basel, Switzerland). 2017; [PubMed PMID: 28468007]|
|||Heneghan MA,Yeoman AD,Verma S,Smith AD,Longhi MS, Autoimmune hepatitis. Lancet (London, England). 2013 Oct 26; [PubMed PMID: 23768844]|
|||Czaja AJ,Donaldson PT, Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. The American journal of gastroenterology. 2002 Aug; [PubMed PMID: 12190176]|
|||Terrabuio DR,Abrantes-Lemos CP,Carrilho FJ,Cançado EL, Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. Journal of clinical gastroenterology. 2009 Apr; [PubMed PMID: 19077726]|
|||Krawitt EL, Autoimmune hepatitis. The New England journal of medicine. 2006 Jan 5; [PubMed PMID: 16394302]|
|||Muratori P,Granito A,Quarneti C,Ferri S,Menichella R,Cassani F,Pappas G,Bianchi FB,Lenzi M,Muratori L, Autoimmune hepatitis in Italy: the Bologna experience. Journal of hepatology. 2009 Jun; [PubMed PMID: 19395113]|
|||Kessler WR,Cummings OW,Eckert G,Chalasani N,Lumeng L,Kwo PY, Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2004 Jul; [PubMed PMID: 15224287]|
|||Bower WA,Johns M,Margolis HS,Williams IT,Bell BP, Population-based surveillance for acute liver failure. The American journal of gastroenterology. 2007 Nov; [PubMed PMID: 17608778]|
|||Anand L,Choudhury A,Bihari C,Sharma BC,Kumar M,Maiwall R,Siam Tan S,Shah SR,Hamid S,Butt AS,Jafri W,Chawla YK,Taneja S,Duseja A,Dhiman RK,Mahtab MA,Ghazinyan H,Duan Z,Chen Y,Shukla A,Hu J,Abbas Z,Treeprasertsuk S,Lesmana LA,Lesmana CR,Sollano JD,Carpio G,Sahu MK,Kumar G,Sarin SK, Flare of Autoimmune Hepatitis Causing Acute on Chronic Liver Failure: Diagnosis and Response to Corticosteroid Therapy. Hepatology (Baltimore, Md.). 2018 Aug 16; [PubMed PMID: 30113706]|
|||Bittencourt PL,Farias AQ,Porta G,Cançado EL,Miura I,Pugliese R,Kalil J,Goldberg AC,Carrilho FJ, Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background. Journal of clinical gastroenterology. 2008 Mar; [PubMed PMID: 18223493]|
|||Teufel A,Weinmann A,Kahaly GJ,Centner C,Piendl A,Wörns M,Lohse AW,Galle PR,Kanzler S, Concurrent autoimmune diseases in patients with autoimmune hepatitis. Journal of clinical gastroenterology. 2010 Mar; [PubMed PMID: 20087196]|
|||Björnsson E,Talwalkar J,Treeprasertsuk S,Neuhauser M,Lindor K, Patients with typical laboratory features of autoimmune hepatitis rarely need a liver biopsy for diagnosis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2011 Jan; [PubMed PMID: 20723617]|
|||Candia L,Marquez J,Espinoza LR, Autoimmune hepatitis and pregnancy: a rheumatologist's dilemma. Seminars in arthritis and rheumatism. 2005 Aug; [PubMed PMID: 16084224]|
|||Esposti SD, Pregnancy in patients with advanced chronic liver disease. Clinical liver disease. 2014 Sep; [PubMed PMID: 30992923]|
|||Westbrook RH,Yeoman AD,O'Grady JG,Harrison PM,Devlin J,Heneghan MA, Model for end-stage liver disease score predicts outcome in cirrhotic patients during pregnancy. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2011 Aug; [PubMed PMID: 21570482]|
|||Shaheen AA,Myers RP, The outcomes of pregnancy in patients with cirrhosis: a population-based study. Liver international : official journal of the International Association for the Study of the Liver. 2010 Feb; [PubMed PMID: 19874491]|
|||Wang Q,Yang F,Miao Q,Krawitt EL,Gershwin ME,Ma X, The clinical phenotypes of autoimmune hepatitis: A comprehensive review. Journal of autoimmunity. 2016 Jan; [PubMed PMID: 26614611]|
|||Ch'ng CL,Morgan M,Hainsworth I,Kingham JG, Prospective study of liver dysfunction in pregnancy in Southwest Wales. Gut. 2002 Dec; [PubMed PMID: 12427793]|